MA5-14744

antibody from Invitrogen Antibodies

Targeting: CRP PTX1

ELISA (Recommended by provider)

Immunocytochemistry (Supportive data in Antibodypedia)

Immunoprecipitation (Recommended by provider)

Radioimmunoassay (Recommended by provider)

Antibody Data

Product number

MA5-14744

Provider

Invitrogen Antibodies

Product name

CRP Monoclonal Antibody (P4D7)

Antibody type

Monoclonal

Antigen

Purifed from natural sources

Description

MA5-14744 targets C Reactive Protein in ELISA, IP, and RIA applications and shows reactivity with Human samples. The MA5-14744 immunogen is purified human plasma CRP. MA5-14744 detects C Reactive Protein which has a predicted molecular weight of approximately 23 kDa. Product MA514744 is a smaller package size of MIC0501 (formerly sold as a Seradyn product).

Reactivity

Human

Host

Mouse

Isotype

IgG

Antibody clone number

P4D7

Vial size

100 µg

Concentration

1 mg/mL

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C

Immunocytochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunofluorescence analysis of CRP was performed using 70% confluent log phase HepG2 cells. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 15 minutes, and blocked with 2% BSA for 45 minutes at room temperature. The cells were labeled with CRP Monoclonal Antibody (P4D7) (Product # MA5-14744, 5 µg/mL) in 0.1% BSA, incubated at 4 degree celsius overnight and then labeled with Donkey anti-Mouse IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor Plus 488 (Product # A32766, 1:2000 dilution), for 45 minutes at room temperature (Panels a,e,i: Green). Nuclei (Panels b,f,j: Blue) were stained with ProLong™ Diamond Antifade Mountant with DAPI (Product # P36962). F-actin (Panels c,g,k: Red) was stained with Rhodamine Phalloidin (Product # R415, 1:300 dilution). Panels d,h,l represents the merged images showing cytoplasmic localization upon treatment with IL-6 and PTI. Panel (a-d) shows representative HepG2 control cells, whereas Panel (e-h) represent HepG2 with Protein Transport Inhibitor Cocktail (PTI)(500X) (1X, 4 hours) treatment. Similarly, panel (i-l) represent HepG2 cells treated with IL-6 and Protein Transport Inhibitor Cocktail (PTI)(500X) (10 ng/mL, 1X; 24 hours, 4 hours). The images were captured at 60X magnification.